Brief: Jacobio Will Present Phase I Clinical Data Of Kras G12c Inhibitor Jab-21822 At The 2022 Asco Annual Meeting
27/05/2022 20:00
Jacobio Pharmaceuticals Group Co Ltd 1167.HK :
* JACOBIO WILL PRESENT PHASE I CLINICAL DATA OF KRAS G12C
INHIBITOR JAB-21822 AT THE 2022 ASCO ANNUAL MEETING
Source text for Eikon: ID:nPn6SSfTWa
Further company coverage: 1167.HK
Recent news on Jacobio Pharmaceuticals
See all newsBrief: Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice Chairperson
China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Brief: Jacobio Pharmaceuticals Group Posts H1 Net Income Attributable RMB 600.6 Million
Brief: Jacobio Pharmaceuticals Expects HY Net Profit Of Not Less Than RMB600 Million
HK-listed Jacobio Pharmaceuticals climbs on share buyback plan